Skip to Page Content

The ONLY conference where you can have face-to-face dialogue with top policy makers and executives on how to drive your pre- and post-regulatory approval and commercialization strategies.

Don't fall behind the curve. Seating is limited. Register online today and save!

December 8-9, 2011
The Mayflower Renaissance
Washington, DC

Add to Outlook Add to Outlook Calender

Follow Us:

LinkedIn Facebook Twitter
General Registration General Registration Government Registration

Welcome to the Real World: Innovating in a Rapidly Changing Policy Climate


Post-marketing safety regulation. Comparative effectiveness research. FDA/CMS parallel reviews.

What do all these public policy buzzwords have in common? The need to understand--and influence--the impact of pharmaceuticals in actual practice, rather than in the pristine setting of clinical trials.

When it comes to new public policy ideas and new pharmaceutical products, the big test is always the same: what happens when you try something new in the real world? Whether it is years of carefully controlled clinical research or decades of public policy debate, no one can be sure what will happen when a new product enters the marketplace, or a new public policy idea becomes law.

This is the real world: Health care reform is law. Biosimilars are coming. A new user fee deal is pending. Federal budget deficits are overwhelming.

How will all these factors affect the reality of the pharmaceutical business in the years to come? Join us at the seventh annual FDA/CMS Summit for Biopharma Executives to find out.

If you make FDA/CMS Summit an annual must-attend like hundreds of other pharmaceutical and biotech leaders, keep ahead of the curve and mark your calendars NOW.

 

NEW for 2011! Hear the Regulators' First-Hand Perspectives on:

  • New Drug Reviews
  • Pre- and post-market review process
  • Biosimilars/follow-on biologics
  • "Real World" data sets
  • Formulary Management
  • ACOs
  • Cancer Drug Coverage
  • Health Care Reform
  • PDUFA V
  • Comparative Effectiveness Research
  • HCR Implementation
  • Payor Issues
  • Drug safety, risk management, & post-market surveillance
  • Pharma marketing and promotions regulation and enforcement
  • Medicaid and Medicare reimbursement
  • Pricing Strategies

Key Benefits for Attending FDA/CMS Summit:

  • Hear about critical trends and changes so you can create successful strategies for dealing with FDA and CMS
  • Walk away with practical, real life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles
  • Get face-to-face access to the top regulatory thought leaders and policy makers
  • Benchmark your regulatory strategy against all the major pharmaceutical and biotech companies

 

Here is what your peers have to say about FDA/CMS Summit:

“I would like to thank the whole Windhover/RPM team for putting together this conference. Conferences are made by its participants and the group assembled here today is so diverse and truly experienced.” – Mark McClellan, MD/PhD, Former FDA Commissioner and CMS Administrator

View other testimonials »»

Special Keynote Address Speakers:
Martin Mackay Martin Mackay
President
Research & Development
AstraZeneca Pharmaceuticals
Steven Spielberg Steven Spielberg
Deputy Commissioner for Medical Products & Tobacco
Food & Drug Administration (FDA)
Karen Midthun Karen Midthun, M.D.
Director Center for Biologics Evaluation and Research
Food & Drug Administration (FDA)

View Complete List of Speakers »»

 

 

Cancellation Policy: The last day to cancel your registration for a refund, minus a $300 processing fee, is November 1, 2011. After that, you may send another delegate from your company.